CN1217190C - 引起精神障碍的中枢神经系统疾病中smr1-nep相互作用的调节 - Google Patents
引起精神障碍的中枢神经系统疾病中smr1-nep相互作用的调节 Download PDFInfo
- Publication number
- CN1217190C CN1217190C CN018212654A CN01821265A CN1217190C CN 1217190 C CN1217190 C CN 1217190C CN 018212654 A CN018212654 A CN 018212654A CN 01821265 A CN01821265 A CN 01821265A CN 1217190 C CN1217190 C CN 1217190C
- Authority
- CN
- China
- Prior art keywords
- nep
- peptide
- qhnpr
- smr1
- under
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
- G01N33/567—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds utilising isolate of tissue or organ as binding agent
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cardiology (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
Abstract
Description
预孵育时间 | 10分钟(膜制备物);15分钟(新鲜组织切片) |
孵育时间 | 5-30分钟 |
温度 | 25℃ |
膜或组织蛋白(脊髓)的终浓度 | 1mg/ml |
底物浓度 | P物质:12.5nM;Met-脑啡肽:10μM(HPLC),20nM(RIA) |
反应体积 | 1ml(新鲜组织切片);250μl(膜制备物) |
分离代谢物的技术 | Sep-Pak+液体闪烁计(3H-P物质);RP-HPLC和RIA(Met-脑啡肽) |
缓冲液 | Trls-HCI 50mM,pH7.2+BSA 0.1%+Bestatln10μM(膜制备物);KRBG+BSA 0.1%+Bestatin 10μM(氧化的,环境为95%02-5%CO2)(新鲜组织切片) |
组 | 大鼠/组 | 处理 | 剂量(μg/kg) | 体积(ml/kg) | 重复测验前施用时间(分钟) |
载体 | 10 | 醋酸+PBS | - | 0.7 | 1440,300,5 |
FG50 | 10 | FG-005 | 50 | 0.7 | 1440,300,5 |
FG100 | 10 | FG-005 | 100 | 0.7 | 1440,300,5 |
8-OH-DPAT | 10 | 8-OH-DPAT | 500 | 1 | 1440,300,30 |
载体 | FG-50 | FG-100 | 8-OH-DPAT | |
i.v.(n=10) | 50μg/kg,i.v.(n=10) | 100μg/kg,i.v.(n=10) | 0.5mg/kg,i.p.(n=10) | |
测验 | 104.80±11.08 | 119.00±13.79 | 138.30±11.03 | 109.20±11.43 |
重复测验 | 187.80±20.41 | 141.20±21.28 | 121.50±17.47 | 31.60±11.51 |
配对t检验(双侧概率)(测验vs.重复测验) | t=4.14;p<0.005 | t=1.50;NS | t=1.20;NS | t=10.91;p<0.001 |
Claims (3)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00403670A EP1216707B1 (en) | 2000-12-22 | 2000-12-22 | Process for screening ligand molecules that specifically bind to the NEP binding site for the QHNPR pentapeptide |
EP00403670.3 | 2000-12-22 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1482918A CN1482918A (zh) | 2004-03-17 |
CN1217190C true CN1217190C (zh) | 2005-08-31 |
Family
ID=8174003
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN018212654A Expired - Fee Related CN1217190C (zh) | 2000-12-22 | 2001-12-24 | 引起精神障碍的中枢神经系统疾病中smr1-nep相互作用的调节 |
CNB018212646A Expired - Fee Related CN1229137C (zh) | 2000-12-22 | 2001-12-24 | Smr1肽的新的治疗用途 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB018212646A Expired - Fee Related CN1229137C (zh) | 2000-12-22 | 2001-12-24 | Smr1肽的新的治疗用途 |
Country Status (12)
Country | Link |
---|---|
US (4) | US7423020B2 (zh) |
EP (3) | EP1216707B1 (zh) |
JP (4) | JP4409831B2 (zh) |
CN (2) | CN1217190C (zh) |
AT (2) | ATE288763T1 (zh) |
AU (2) | AU2002236100A1 (zh) |
CA (2) | CA2431913A1 (zh) |
DE (2) | DE60018085T2 (zh) |
DK (1) | DK1216707T3 (zh) |
ES (2) | ES2235806T3 (zh) |
PT (1) | PT1216707E (zh) |
WO (2) | WO2002051434A2 (zh) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6589750B2 (en) * | 1997-02-20 | 2003-07-08 | Institut Pasteur | Therapeutic use of the SMR1 protein, the SMR1 maturation products, specifically the QHNPR pentapeptide as well as its biologically active derivatives |
AU6154700A (en) | 1999-06-23 | 2001-01-31 | Centre National De La Recherche Scientifique (C.N.R.S.) | Therapeutic methods and compositions for the treatment of impaired interpersonal and behavioral disorders |
ES2235806T3 (es) * | 2000-12-22 | 2005-07-16 | Institut Pasteur | Procedimiento de seleccion de moleculas ligando que se unen especificamente al sitio de union nep para el prentapeptido qhnpr. |
ATE429909T1 (de) * | 2002-05-29 | 2009-05-15 | Merck & Co Inc | Nützliche verbindungen für die behandlung von anthrax und hemmung des letalen faktors |
US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
SI1594517T1 (sl) | 2003-01-28 | 2007-10-31 | Microbia Inc | Sestavki za zdravljenje gastrointestinalnih motenj |
EP1577320B1 (en) * | 2004-03-19 | 2012-07-18 | Institut Pasteur | Peptides derived from human BPLP protein, polynucleotides coding for said peptides and antibodies directed against said peptides |
EP1747212A4 (en) * | 2004-05-11 | 2009-03-25 | Merck & Co Inc | PROCESS FOR PRODUCING N-SULFINATED AMINO ACID DERIVATIVES |
US20100003276A1 (en) * | 2004-12-07 | 2010-01-07 | Hermes Jeffery D | Methods for treating anthrax and inhibiting lethal factor |
EA020466B1 (ru) | 2007-06-04 | 2014-11-28 | Синерджи Фармасьютикалз Инк. | Агонисты гуанилатциклазы, пригодные для лечения желудочно-кишечных нарушений, воспаления, рака и других заболеваний |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
RU2542365C2 (ru) * | 2008-04-07 | 2015-02-20 | Энститю Пастёр | Производные опиорфинного пептида как потенциальные ингибиторы эктопептидаз, участвующих в деградации энкефалинов |
FR2931362B1 (fr) | 2008-05-26 | 2017-08-18 | Pasteur Institut | L'opiorphine pour une utilisation en tant que psychostimulant. |
CA2726917C (en) | 2008-06-04 | 2018-06-26 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
CA2730603C (en) | 2008-07-16 | 2019-09-24 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
CA2645452A1 (en) * | 2008-11-28 | 2010-05-28 | Institut Pasteur | Use of basic prolin-rich lacrimal gene products, such as opiorphin, as a biomarker |
CA2994066A1 (en) | 2008-12-03 | 2010-06-10 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase c agonists and methods of use |
US8506544B2 (en) | 2010-06-21 | 2013-08-13 | The Procter & Gamble Company | Disposable absorbent pant with efficient design and convenient single-section side stretch panels |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
WO2012118972A2 (en) | 2011-03-01 | 2012-09-07 | Synegy Pharmaceuticals Inc. | Process of preparing guanylate cyclase c agonists |
EP2970384A1 (en) | 2013-03-15 | 2016-01-20 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
CA2905435A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
CN113388007A (zh) | 2013-06-05 | 2021-09-14 | 博士医疗爱尔兰有限公司 | 鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US738778A (en) * | 1903-05-22 | 1903-09-15 | Cottrell C B & Sons Co | Sheet-delivery apparatus for printing and folding machinery. |
EP0288897B1 (de) * | 1987-04-25 | 1993-08-11 | Hoechst Aktiengesellschaft | Enkastine: Neue Glycopeptide mit Enkephalinase-hemmender Wirkung, Verfahren zu ihrer Herstellung und ihre Verwendung als pharmazeutische Präparate |
FR2637600B1 (fr) | 1988-10-11 | 1992-03-06 | Pasteur Institut | Peptides et polypeptides provenant de la glande sous maxillaire du rat, anticorps monoclonaux et polyclonaux correspondants, hybridomes correspondants et applications de ces produits au diagnostic, a la detection ou a des fins therapeutiques |
US5550119A (en) * | 1995-03-02 | 1996-08-27 | Ciba-Geigy Corporation | Phosphono substituted tetrazole derivatives as ECE inhibitors |
US6589750B2 (en) | 1997-02-20 | 2003-07-08 | Institut Pasteur | Therapeutic use of the SMR1 protein, the SMR1 maturation products, specifically the QHNPR pentapeptide as well as its biologically active derivatives |
AU6154700A (en) | 1999-06-23 | 2001-01-31 | Centre National De La Recherche Scientifique (C.N.R.S.) | Therapeutic methods and compositions for the treatment of impaired interpersonal and behavioral disorders |
ES2235806T3 (es) * | 2000-12-22 | 2005-07-16 | Institut Pasteur | Procedimiento de seleccion de moleculas ligando que se unen especificamente al sitio de union nep para el prentapeptido qhnpr. |
-
2000
- 2000-12-22 ES ES00403670T patent/ES2235806T3/es not_active Expired - Lifetime
- 2000-12-22 EP EP00403670A patent/EP1216707B1/en not_active Expired - Lifetime
- 2000-12-22 PT PT00403670T patent/PT1216707E/pt unknown
- 2000-12-22 DE DE60018085T patent/DE60018085T2/de not_active Expired - Lifetime
- 2000-12-22 AT AT00403670T patent/ATE288763T1/de active
- 2000-12-22 DK DK00403670T patent/DK1216707T3/da active
-
2001
- 2001-12-24 CA CA002431913A patent/CA2431913A1/en not_active Abandoned
- 2001-12-24 EP EP01985936A patent/EP1343520B1/en not_active Expired - Lifetime
- 2001-12-24 AU AU2002236100A patent/AU2002236100A1/en not_active Abandoned
- 2001-12-24 ES ES01985936T patent/ES2363708T3/es not_active Expired - Lifetime
- 2001-12-24 DE DE60143990T patent/DE60143990D1/de not_active Expired - Lifetime
- 2001-12-24 JP JP2002552577A patent/JP4409831B2/ja not_active Expired - Fee Related
- 2001-12-24 CN CN018212654A patent/CN1217190C/zh not_active Expired - Fee Related
- 2001-12-24 EP EP01985459A patent/EP1343519A2/en not_active Withdrawn
- 2001-12-24 WO PCT/IB2001/002818 patent/WO2002051434A2/en active Application Filing
- 2001-12-24 WO PCT/IB2001/002819 patent/WO2002051435A2/en active Application Filing
- 2001-12-24 JP JP2002552576A patent/JP4347566B2/ja not_active Expired - Fee Related
- 2001-12-24 CN CNB018212646A patent/CN1229137C/zh not_active Expired - Fee Related
- 2001-12-24 CA CA2431916A patent/CA2431916C/en not_active Expired - Lifetime
- 2001-12-24 US US10/451,073 patent/US7423020B2/en not_active Expired - Fee Related
- 2001-12-24 AT AT01985936T patent/ATE497390T1/de active
- 2001-12-24 AU AU2002234806A patent/AU2002234806A1/en not_active Abandoned
- 2001-12-24 US US10/451,064 patent/US7153833B2/en not_active Expired - Lifetime
-
2006
- 2006-11-08 US US11/594,105 patent/US7625713B2/en not_active Expired - Fee Related
-
2008
- 2008-06-06 JP JP2008149611A patent/JP2009007352A/ja active Pending
- 2008-11-28 JP JP2008305315A patent/JP2009149633A/ja active Pending
-
2009
- 2009-10-16 US US12/580,701 patent/US20100041072A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1217190C (zh) | 引起精神障碍的中枢神经系统疾病中smr1-nep相互作用的调节 | |
Roques | Novel approaches to targeting neuropeptide systems | |
Xu et al. | Neuropeptide S: a neuropeptide promoting arousal and anxiolytic-like effects | |
McLean | Do substance P and the NK1 receptor have a role in depression and anxiety? | |
CN105079781A (zh) | 用于治疗乳糜泻的组合物和方法 | |
Björnfot Holmström et al. | Gingival tissue inflammation promotes increased matrix metalloproteinase-12 production by cd200rlow monocyte-derived cells in periodontitis | |
Natsch | What makes us smell: the biochemistry of body odour and the design of new deodorant ingredients | |
WO2005000335A2 (en) | Use of genes differentially expressed during aging of liver for treatment and diagnosis | |
Lee et al. | A Japanese child with geleophysic dysplasia caused by a novel mutation of FBN1 | |
WO2006023121A1 (en) | Diagnosis of hyperinsulinemia and type ii diabetes and protection against same based on genes differentially expressed in white adipose tissue (13) | |
CN1856504A (zh) | 抗梗塞分子 | |
JP2006518211A (ja) | ボツリヌストキシンの定量化 | |
EP1613777A1 (en) | Diagnosis of hyperinsulinemia and type ii diabetes and protection against same | |
JP5176229B2 (ja) | アレルギー疾患の治療薬且つ治療効果のマーカー | |
CA2577176A1 (en) | Method of screening for a carnitine transporter agonist or antagonist and its uses | |
Mérignac-Lacombe et al. | Characterization of a Human Respiratory Mucosa Model to Study Odorant Metabolism | |
CN1812786A (zh) | 吡唑并吡啶在治疗认知缺陷中的应用 | |
Layden et al. | A biomimetic C-terminal extension strategy for photocaging amidated neuropeptides | |
Ichiki et al. | Neurokinin B activates the formation and bone resorption activity of rat osteoclasts | |
Nolte et al. | Proceedings of the 2020 Classic Examples in Toxicologic Pathology XXVII | |
Reich et al. | New Insights into the Pathogenesis of Psoriasis. | |
Karl et al. | Loss of stress-induced analgesia in rat models of dipeptidyl peptidase 4 deficiency: Evidence for mediation via stress-protective effects of NPY | |
Thompson | Mediators and markers of mammalian lifespan extension: Proteomic, proliferative and hormonal adaptations in mouse models of extended lifespan | |
Goodwin | beta-amyloid-mediated nitric oxide release from rat microglia by ligation of the integrin Mac-1 | |
Radu | Aspects on the psychopharmacology of cholecystokinin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CI01 | Publication of corrected invention patent application |
Correction item: Denomination of Invention Correct: Regulation of SMRl-NEP interaction in central nervous system diseases causing mental disorders False: Regulation of SMRI-NEP interaction in central nervous system diseases causing mental disorders Number: 11 Volume: 20 |
|
CI02 | Correction of invention patent application |
Correction item: Denomination of Invention Correct: Regulation of SMRl-NEP interaction in central nervous system diseases causing mental disorders False: Regulation of SMRI-NEP interaction in central nervous system diseases causing mental disorders Number: 11 Page: The title page Volume: 20 |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20050831 Termination date: 20111224 |